The introduction of biosimilars of low molecular weight heparins in Europe: a critical review and reappraisal endorsed by the Italian Society for Haemostasis and Thrombosis (SISET) and the Italian Society for Angiology and Vascular Medicine (SIAPAV)

The introduction of biosimilars of low molecular weight heparins in Europe: a critical review and reappraisal endorsed by the Italian Society for Haemostasis and Thrombosis (SISET) and the Italian Society for Angiology and Vascular Medicine (SIAPAV)

Abstract Recently, the European Medicines Agency (EMA) authorized the introduction and marketing of Thorinane® and Inhixa®, biosimilars of the Low Molecular Weight Heparin (LMWH) enoxaparin. The authorization path is considerably different from the guidelines published by the EMA in 2009, as well as...

Full description

Bibliographic Details
Main Authors: Davide Imberti, Marco Marietta, Hernan Polo Friz, Claudio Cimminiello
Format: Article
Language:English
Published: BMC 2017-05-01
Series:Thrombosis Journal
Subjects:
Low molecular weight heparin
Biosimilar pharmaceuticals
Evidence-based practice
Therapeutic equivalency
Venous Thromboembolism
Online Access:http://link.springer.com/article/10.1186/s12959-017-0136-2

Internet

http://link.springer.com/article/10.1186/s12959-017-0136-2

Similar Items